A Phase 2 Randomized, Open-Label Study of GS-5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) to Treatment-Naive Subjects With Chronic Genotype 1 HCV Infection.
Phase of Trial: Phase II
Latest Information Update: 26 Apr 2015
At a glance
- Drugs Ledipasvir (Primary) ; Vedroprevir (Primary) ; Peginterferon alfa-2a; Ribavirin; Tegobuvir
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 05 Feb 2014 Results published in Hepatology.
- 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Apr 2012 Interim safety and efficacy data will be presented at the 47th Annual Meeting of the European Association for the Study of the Liver (EASL), according to a Gilead Sciences media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History